Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176382 · ClinicalTrials.gov registry record · Phase 4
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
NCT02176382: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02176382 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02176382, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
Study Summary
The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide. The study extension will evaluate the effect of one-dose of zoledronic acid after the teriparatide/denosumab combination.
Interventions
- DRUG Zoledronic acid
- DRUG denosumab
- DRUG teriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-08 |
| Est. Completion | 2020-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02176382
The ClinicalTrials.gov registry entry for NCT02176382 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zoledronic acid is the first listed.
NCT02176382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02176382 about?
NCT02176382 is a clinical study titled "Denosumab and Teriparatide Study (DATA-HD and DATA-EX)". The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide. The study extension will evaluate the effect of one-dose of zoledronic acid after the teriparatide/denosumab combination.
What is the current status of trial NCT02176382?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2014-08. Estimated completion is 2020-02.
What interventions are being tested in trial NCT02176382?
The interventions under investigation include: Zoledronic acid (DRUG), denosumab (DRUG), teriparatide (DRUG).
Who is sponsoring clinical trial NCT02176382?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.